Svensson K, Johansson A M, Magnusson T, Carlsson A
Naunyn Schmiedebergs Arch Pharmacol. 1986 Nov;334(3):234-45. doi: 10.1007/BF00508777.
The biochemical and behavioral effects of the putative dopamine autoreceptor antagonists cis-(+)-5-methoxy-1-methyl-2-(n-propylamino)tetralin, (+)-AJ 76 and cis-(+)-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin, (+)-UH 232, were evaluated in various in vivo models in rats. Both compounds produced a marked elevation in brain dopamine synthesis and turnover with only slight effects on the synthesis and turnover of serotonin (5-HT) and noradrenaline being noted. (+)-AJ 76 and (+)-UH 232 also failed to antagonize the decrease in cortical noradrenaline synthesis rate caused by the alpha 2 agonist clonidine. The apomorphine-induced decrease in dopamine synthesis rate in gamma-butyrolactone (GBL) treated animals was completely blocked by (+)-AJ 76 and (+)-UH 232 but not by d-amphetamine or methylphenidate. In activity experiments using habituated animals, (+)-AJ 76 and (+)-UH 232 produced locomotor stimulation and weak stereotypies and antagonized the sedative effects of low doses of apomorphine. Locomotor hyperactivity induced by apomorphine or the dopamine agonist DiPr-5,6-ADTN was antagonized by (+)-UH 232 and to a lesser degree by (+)-AJ 76. The locomotor hyperactivity produced by (+)-AJ 76, (+)-UH 232 and methylphenidate was completely prevented by reserpine pretreatment and partially blocked by the tyrosine hydroxylase inhibitor alpha-methyl-para-tyrosine (alpha-MT), whereas d-amphetamine-induced hyperactivity was only antagonized by alpha-MT pretreatment. It is concluded that (+)-AJ 76 and (+)-UH 232 produce behavioral stimulation via a preferential antagonism on central dopamine autoreceptors, an action different from that of all known stimulants including apomorphine, d-amphetamine and methylphenidate. (+)-AJ 76 and (+)-UH 232 possess but weak antagonistic effects on postsynaptic dopamine receptors and only the latter compound is able to induce sedation in rats.
在大鼠的多种体内模型中评估了假定的多巴胺自身受体拮抗剂顺式-(+)-5-甲氧基-1-甲基-2-(正丙基氨基)四氢萘((+)-AJ 76)和顺式-(+)-5-甲氧基-1-甲基-2-(二正丙基氨基)四氢萘((+)-UH 232)的生化和行为效应。两种化合物均使脑内多巴胺合成和周转率显著升高,而对血清素(5-HT)和去甲肾上腺素的合成及周转率仅有轻微影响。(+)-AJ 76和(+)-UH 232也未能拮抗α2激动剂可乐定引起的皮质去甲肾上腺素合成速率降低。在γ-丁内酯(GBL)处理的动物中,阿扑吗啡诱导的多巴胺合成速率降低被(+)-AJ 76和(+)-UH 232完全阻断,但未被右旋苯丙胺或哌醋甲酯阻断。在使用习惯化动物的活动实验中,(+)-AJ 76和(+)-UH 232产生运动兴奋和轻度刻板行为,并拮抗低剂量阿扑吗啡的镇静作用。阿扑吗啡或多巴胺激动剂DiPr-5,6-ADTN诱导的运动过度被(+)-UH 232拮抗,(+)-AJ 76的拮抗作用较小。利血平预处理可完全阻止(+)-AJ 76、(+)-UH 232和哌醋甲酯产生的运动过度,酪氨酸羟化酶抑制剂α-甲基-对酪氨酸(α-MT)可部分阻断,而右旋苯丙胺诱导的运动过度仅被α-MT预处理拮抗。得出结论,(+)-AJ 76和(+)-UH 232通过对中枢多巴胺自身受体的优先拮抗产生行为兴奋,这一作用不同于包括阿扑吗啡、右旋苯丙胺和哌醋甲酯在内的所有已知兴奋剂。(+)-AJ 76和(+)-UH 232对突触后多巴胺受体仅有微弱的拮抗作用,且只有后者化合物能够在大鼠中诱导镇静。